Gilead's Plan? Cash In on CAR-T
Investors eagerly awaiting news of how Gilead Sciences' (NASDAQ: GILD) plans to spend its growing mountain of cash found out on Monday that the company's plans to become a leader in cancer treatment weren't lip-service. Management will spend $11.9 billion to acquire Kite Pharma (NASDAQ: KITE), a promising clinical-stage drug company developing a new approach to kill cancer called CAR-T.
Chimeric antigen receptor T-cell therapy, or CAR-T for short, is a complex approach to beating back cancer that involves re-engineering a patient's T-cells so that they can better find and destroy cancer cells.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€70.94
0.440%
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 85 € shows a slightly positive potential of 19.82% compared to the current price of 70.94 € for Gilead Sciences Inc.
